Evidence map›Paper›PMID 28802087›Full record

Trial reportPediatric blood & cancer2018

Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group.

Ramona Vesna Untanu, Jason Back, Burton Appel, Qinglin Pei, Lu Chen, Allen Buxton, David C Hodgson, Peter F Ehrlich, Louis S Constine, Cindy L Schwartz and 1 more

Open access · greenAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric blood & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Diagnosis of Hodgkin lymphoma in the modern era.British journal of haematology · 2019
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Ramona Vesna UntanuDivision of Clinical Pathology, Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York.
Jason BackDivision of Clinical Pathology, Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York.
Burton AppelHematology/Oncology, Institute for Pediatric Cancer & Blood Disorders, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey.
Qinglin PeiChildren's Oncology Group, Department of Biostatistics, University of Florida, Gainesville, Florida.
Lu ChenDepartment of Information Sciences, City of Hope, Duarte, California.
Allen BuxtonStatistics, Children's Oncology Group, Monrovia, California.
David C HodgsonRadiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Peter F EhrlichDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.
Louis S ConstineDepartment of Radiation Oncology, University of Rochester, Rochester, New York.
Cindy L SchwartzChildren's Hospital of Wisconsin, Department of Oncology, Milwaukee, WI, University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert E HutchisonDivision of Clinical Pathology, Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York.ORCID http://orcid.org/0000-0002-1704-8006
SUNY Upstate Medical University · USChildren's Hospital of Wisconsin · USChildren's Oncology Group · CHChildren's Oncology Group · USCity of Hope · USHackensack University Medical Center · USPrincess Margaret Cancer Centre · CAUniversity of Michigan · USUniversity of Rochester · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundHistologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample.

resultsFifty-eight (35.1%) cases showed only typical nodular with or without serpiginous histology (types A and B). The remainder showed mixtures of histologies. The numbers of patients with score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type C), 3 with T-cell-rich nodular pattern (type D), 55 (32.7%) with diffuse T-cell-rich (type E) pattern, and 2 (1.2%) with diffuse B-cell pattern (type F). Higher level of types C (P = 0.048) and D (P = 0.033) resulted in lower event-free survival (EFS). Cytoplasmic IgD was found in 65 of 130 tested (50%), did not significantly associate with EFS but positively correlated with types C and E histology (P < 0.0001) and negatively correlated with types A (P = 0.0003) and B (P = 0.006). Seventeen (10%) expressed CD30, with no adverse effect.

conclusionsVariant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.

Indexed as

B-LymphocytesGene Expression Regulation, NeoplasticHodgkin DiseaseT-LymphocytesAdolescentChildChild, PreschoolDisease-Free SurvivalFemaleHumansImmunoglobulin DImmunohistochemistryInfantInfant, NewbornKi-1 AntigenMaleImmunoglobulin DKi-1 AntigenchildrenhistologyHodgkinlymphomapathology

Identifiers

PMID28802087
PMCPMC5699946
OpenAlexW2744822218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.